We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+33.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.72B
AUM Growth
-$71.4M
(-2.6%)
Cap. Flow
-$452M
Cap. Flow
% of AUM
-16.6%
Top 10 Holdings %
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Avg Time Held
2.6
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Silence Therapeutics
SLN
|
+$44.1M |
| 2 |
Keros Therapeutics
KROS
|
+$32.8M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$32.2M |
| 4 |
Cigna
CI
|
+$21.5M |
| 5 |
Immunome
IMNM
|
+$20.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunogen Inc
IMGN
|
+$487M |
| 2 |
RayzeBio, Inc. Common Stock
RYZB
|
+$115M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$67.7M |
| 4 |
Krystal Biotech
KRYS
|
+$31.2M |
| 5 |
CATALENT, INC.
CTLT
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.54% |
| 2 | Industrials | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
DELISTED
HOOKIPA Pharma
HOOK
| $757K | 0.03% |
106,377
| – | – |
2019 Q2
19 quarters
|
|
77
Alpha Teknova
TKNO
$408M
| $434K | 0.02% |
171,453
+10,448
| +6% | +$32.4K |
2021 Q2
11 quarters
|
|
78
Charles River Laboratories
CRL
$14.6B
| – | – |
-86,782
| Closed | -$20.5M | – |
|
|
79
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| – | – |
-142,500
| Closed | -$67.7M | – |
|
|
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| – | – |
-442,653
| Closed | -$58.4K | – |
|
|
SNCE
81
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| – | – |
-990,412
| Closed | -$5.29M | – |
|
|
82
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-1,857,706
| Closed | -$115M | – |
|
|
MDVL
83
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| – | – |
-692,082
| Closed | -$3.05M | – |
|
|
84
DELISTED
Immunogen Inc
IMGN
| – | – |
-16,423,922
| Closed | -$487M | – |
|
|
NVTA
85
DELISTED
Invitae Corporation
NVTA
| – | – |
-1,474,026
| Closed | -$924K | – |
|
|
SLGC
86
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| – | – |
-370,839
| Closed | -$938K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2024 Portfolio in Review
As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.
Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.
- Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
- Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
- Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
- Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
- Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
- Redmile Group opened 16 new positions and closed 9 in Q1 2024.
- Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.
Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.